We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biologics Introduces Clinical Policy and Therapeutic Intelligence Office
News

Biologics Introduces Clinical Policy and Therapeutic Intelligence Office

Biologics Introduces Clinical Policy and Therapeutic Intelligence Office
News

Biologics Introduces Clinical Policy and Therapeutic Intelligence Office

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biologics Introduces Clinical Policy and Therapeutic Intelligence Office"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The department has been established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in complex disease medical management and pharmacy services, specifically within the oncology sector. Leading this initiative will be Ann Steagall, BSN, RN, OCN, Director of Clinical Policy and Mike James, RPh, PhD, Director of Therapeutic Intelligence.
Primary objectives for the department will be to lead the clinical oversight committee, develop care plans and clinical assessments, and facilitate training for clinical and non-clinical Biologics team members and clients.

“Over the years we have discussed the importance of Biologics leading with our clinical expertise both internally and externally. Additionally, it has long been our objective for Biologics to be considered a teaching organization,” said Stuart Frantz, President & Chief Executive Officer at Biologics. “Combine those two concepts and you have the Clinical Policy and Therapeutic Intelligence Office.”

As Director of Clinical Policy, Ann will lead the coordination of all plan language reviews, an important component of the Care Integration program. She will also continue to serve on the Oncology Board of Advisors.

As Director of Therapeutic Intelligence, Mike will assess all new drug entries and expanded uses which include pipeline monitoring. He will support the development of disease specific whitepapers for client and internal education, and will serve on the Oncology Board of Advisors.

Advertisement